EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Emerging Role of Acitretin in Cutaneous Squamous Cell Carcinoma: From Prevention to Treatment

Fujin Zhou, Ziwei Kang, Zhenlin Li, Guorong Yan, Guolong Zhang

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/7110982 ↗
AbstractBibliografische Angaben

Abstract

Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers worldwide, with an increasing incidence that poses a significant public health challenge. Acitretin, a synthetic retinoid clinically used to treat epidermal hyperproliferative disorders, has emerged as a promising therapy for cSCC. This review summarizes current evidence on its efficacy, safety, dosing strategies, discontinuation‐related issues, combination regimens, and underlying mechanisms in cSCC. Available data support its chemopreventive role mainly in immunocompromised patients, whereas evidence in immunocompetent patients remains limited. Dosing regimens vary, and adverse effects include teratogenicity and cutaneous and mucosal toxicity. In some cases, rebound increases in keratinocyte carcinomas have been observed after treatment discontinuation. Combination therapy with photodynamic therapy (PDT) or 5‐fluorouracil (5‐FU) has shown promise in refractory cases. Mechanistically, we emphasize the pivotal role of the cellular retinoic acid‐binding protein II (CRABP‐II) pathway in mediating acitretin’s antitumor effects, along with a range of other pertinent mechanisms. Further research should optimize treatment strategies of acitretin and fully elucidate its therapeutic mechanisms, with the ultimate goal of improving the clinical outcomes of cSCC patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →